Skip to main content
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Care

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes Care
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Original Article

Model of Complications of NIDDM: II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia

  1. Richard C Eastman, MD,
  2. Jonathan C Javitt, MD,
  3. William H Herman, MD,
  4. Erik J Dasbach, PHD,
  5. Catherine Copley-Merriman, MBA,
  6. William Maier, PHD,
  7. Fred Dong,
  8. Diane Manninen, PHD,
  9. Arthur S Zbrozek, MBA,
  10. James Kotsanos, MD,
  11. Sanford A Garfield, PHD and
  12. Maureen Harris, PHD
  1. Division of Diabetes, Endocrinology, Metabolic Diseases Indianapolis, Indiana
  2. National Institute of Diabetes and Digestive and Kidney Diseases Bethesda, Maryland Department of Opthalmology Indianapolis, Indiana
  3. Worthen Center for Eye Care Research, Georgetown University, School of Medicine Washington, D.C. Department of Internal Medicine Indianapolis, Indiana
  4. Division of Endocrinology and Metabolism, University of Michigan, Epidemiology and Outcomes Research Indianapolis, Indiana
  5. Parke-Davis Inc. Ann Arbor, Michigan Merck Inc. Indianapolis, Indiana
  6. Bluebell, Pennsylvania Battelle Inc. Indianapolis, Indiana
  7. Seattle, Washington Bayer Inc. Indianapolis, Indiana
  8. West Haven, Connecticut Eli Lilly Inc. Indianapolis, Indiana
  1. Address correspondence and reprint requests to Richard C. Eastman, MD, Director, Division of Diabetes, Endocrinology, and Metabolic Diseases, NIDDK, Building 31, Room 9A16, 31 Center Dr. MSC 2560, National Institutes of Health, Bethesda, MD 20892-2560.
Diabetes Care 1997 May; 20(5): 735-744. https://doi.org/10.2337/diacare.20.5.735
PreviousNext
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

OBJECTIVE To analyze the health benefits and economics of treating NIDDM with the goal of normoglycemia.

RESEARCH DESIGN AND METHODS Incidence-based simulation model of NIDDM was used. Hazard rates for complications were adjusted for glycemia using risk gradients from the Diabetes Control and Complications Trial. Treatment costs were estimated from national survey data and clinical trials. Incremental costs and benefits were expressed in present value dollars (3% discount rate). Life-years were adjusted for quality of life, yielding quality-adjusted life-years (QALYs).

RESULTS Comprehensive treatment of NIDDM that maintains an HbA1c value of 7.2% is predicted to reduce the cumulative incidence of blindness, end-stage renal disease, and lower-extremity amputation by 72, 87, and 67%, respectively. Cardiovascular disease risk increased by 3% (no effect of treating glycemia is assumed). Life expectancy increased 1.39 years. The cost of treating hyperglycemia increased by almost twofold, which is partially offset by reductions in the cost of complications. The estimated incremental cost/QALY gained is $16,002. Treatment is more cost-effective for those with longer glycemic exposure (earlier onset of diabetes), minorities, and those with higher HbA1c under standard care.

CONCLUSIONS The incremental effectiveness of treating NIDDM with the goal of normoglycemia is estimated to be ∼ $16,000/QALY gained, which is in the range of interventions that are generally considered cost-effective.

  • Received July 29, 1996.
  • Accepted October 28, 1996.
  • Copyright © 1997 by the American Diabetes Association

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this Issue

May 1997, 20(5)
  • Table of Contents
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes Care.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Model of Complications of NIDDM: II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia
(Your Name) has forwarded a page to you from Diabetes Care
(Your Name) thought you would like to see this page from the Diabetes Care web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Model of Complications of NIDDM: II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia
Richard C Eastman, Jonathan C Javitt, William H Herman, Erik J Dasbach, Catherine Copley-Merriman, William Maier, Fred Dong, Diane Manninen, Arthur S Zbrozek, James Kotsanos, Sanford A Garfield, Maureen Harris
Diabetes Care May 1997, 20 (5) 735-744; DOI: 10.2337/diacare.20.5.735

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Model of Complications of NIDDM: II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia
Richard C Eastman, Jonathan C Javitt, William H Herman, Erik J Dasbach, Catherine Copley-Merriman, William Maier, Fred Dong, Diane Manninen, Arthur S Zbrozek, James Kotsanos, Sanford A Garfield, Maureen Harris
Diabetes Care May 1997, 20 (5) 735-744; DOI: 10.2337/diacare.20.5.735
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

Original Article

  • Economic Costs of Diabetes in the U.S. in 2012
  • Retinal Vascular Geometry Predicts Incident Renal Dysfunction in Young People With Type 1 Diabetes
  • Professional Practice Committee 2012
Show more Original Article

Epidemiology/Health Services/Psychosocial Research

  • Economic Costs of Diabetes in the U.S. in 2012
  • Retinal Vascular Geometry Predicts Incident Renal Dysfunction in Young People With Type 1 Diabetes
  • Professional Practice Committee 2012
Show more Epidemiology/Health Services/Psychosocial Research

Similar Articles

Navigate

  • Current Issue
  • Standards of Care Guidelines
  • Online Ahead of Print
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Care Print ISSN: 0149-5992, Online ISSN: 1935-5548.